Cure of Recurrent Ovarian Cancer: A Multicenter Retrospective Study.

IF 4.4 2区医学 Q1 ONCOLOGY

Cancers Pub Date : 2025-09-19 DOI:10.3390/cancers17183069

Masahiro Sumitomo, Yasushi Kotani, Kosuke Murakami, Kaoru Abiko, Kazuko Sakai, Tomoyuki Otani, Akihiko Ueda, Masayo Ukita, Atsuko Taga, Ikuko Emoto, Kentaro Sekiyama, Minami Okudate, Motonori Matsubara, Yukio Yamanishi, Kazuto Nishio, Masaki Mandai, Noriomi Matsumura

{"title":"Cure of Recurrent Ovarian Cancer: A Multicenter Retrospective Study.","authors":"Masahiro Sumitomo, Yasushi Kotani, Kosuke Murakami, Kaoru Abiko, Kazuko Sakai, Tomoyuki Otani, Akihiko Ueda, Masayo Ukita, Atsuko Taga, Ikuko Emoto, Kentaro Sekiyama, Minami Okudate, Motonori Matsubara, Yukio Yamanishi, Kazuto Nishio, Masaki Mandai, Noriomi Matsumura","doi":"10.3390/cancers17183069","DOIUrl":null,"url":null,"abstract":"Background: The prognosis for recurrent ovarian cancer is poor, but a small percentage of patients can be cured. The aim of this study was to clarify the criteria for being cured and the characteristics of cured cases.Methods: Ovarian cancer cases at 2 university hospitals and 8 community hospitals were analyzed to identify patients who were considered cured after complete remission (CR) following recurrence. Analyses of the tumors were performed and included BRCA1/2 mutation analysis.Results: Of the 157 cases of recurrence, 21 (13%) showed no evidence of disease (NED). NED cases had a lower rate of ascites at the initial diagnosis, longer disease-free survival, a higher rate of solitary lesions, and a higher rate of secondary debulking surgery. All CR cases except for one showed no further recurrence when DFS reached 4 years, which was considered a criterion for being cured. The case of relapse occurred after long-term treatment with bevacizumab. Furthermore, 19.4% of the CR cases achieved 4-year DFS, which represents 9.3% of the cases of recurrent ovarian cancer and 2.3% of all cases of ovarian cancer. BRCA mutation analysis of the tumor was possible in 17 of the 30 cases of recurrent ovarian cancer that achieved a 4-year DFS. Pathogenic variants of BRCA were found in 5 of the 11 cases of high-grade serous carcinoma.Conclusions: Approximately 10% of patients with recurrent ovarian cancer achieved a 4-year DFS and were mostly cured. The curing of cases not involving high-grade serous carcinoma (HGSC) was unrelated to the presence of pathogenic BRCA variants.","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 18","pages":""},"PeriodicalIF":4.4000,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12468123/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/cancers17183069","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The prognosis for recurrent ovarian cancer is poor, but a small percentage of patients can be cured. The aim of this study was to clarify the criteria for being cured and the characteristics of cured cases.

Methods: Ovarian cancer cases at 2 university hospitals and 8 community hospitals were analyzed to identify patients who were considered cured after complete remission (CR) following recurrence. Analyses of the tumors were performed and included BRCA1/2 mutation analysis.

Results: Of the 157 cases of recurrence, 21 (13%) showed no evidence of disease (NED). NED cases had a lower rate of ascites at the initial diagnosis, longer disease-free survival, a higher rate of solitary lesions, and a higher rate of secondary debulking surgery. All CR cases except for one showed no further recurrence when DFS reached 4 years, which was considered a criterion for being cured. The case of relapse occurred after long-term treatment with bevacizumab. Furthermore, 19.4% of the CR cases achieved 4-year DFS, which represents 9.3% of the cases of recurrent ovarian cancer and 2.3% of all cases of ovarian cancer. BRCA mutation analysis of the tumor was possible in 17 of the 30 cases of recurrent ovarian cancer that achieved a 4-year DFS. Pathogenic variants of BRCA were found in 5 of the 11 cases of high-grade serous carcinoma.

Conclusions: Approximately 10% of patients with recurrent ovarian cancer achieved a 4-year DFS and were mostly cured. The curing of cases not involving high-grade serous carcinoma (HGSC) was unrelated to the presence of pathogenic BRCA variants.

查看原文本刊更多论文

卵巢癌复发的治疗：一项多中心回顾性研究。

背景：复发性卵巢癌预后较差，但只有一小部分患者是可以治愈的。本研究的目的是阐明治愈的标准和治愈病例的特点。方法：对2所大学附属医院和8所社区附属医院的卵巢癌病例进行分析，确定复发后完全缓解（CR）后认为治愈的患者。对肿瘤进行分析，包括BRCA1/2突变分析。结果：157例复发患者中，21例（13%）无发病迹象（NED）。NED病例在初始诊断时腹水发生率较低，无病生存期较长，单发病变发生率较高，二次减容手术发生率较高。当DFS达到4年时，除1例外，所有CR病例均无进一步复发，这被认为是治愈的标准。本例复发发生在贝伐单抗长期治疗后。此外，19.4%的CR病例达到了4年的DFS，占复发卵巢癌病例的9.3%，占所有卵巢癌病例的2.3%。在达到4年DFS的30例复发卵巢癌中，有17例可以进行肿瘤的BRCA突变分析。11例高级别浆液性癌中有5例发现BRCA致病性变异。结论：大约10%的复发性卵巢癌患者达到了4年的DFS，并且大部分被治愈。不涉及高级别浆液性癌（HGSC）的病例的治愈与致病性BRCA变异的存在无关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancers Medicine-Oncology

CiteScore

8.00

自引率

9.60%

发文量

5371

审稿时长

18.07 days

期刊介绍： Cancers (ISSN 2072-6694) is an international, peer-reviewed open access journal on oncology. It publishes reviews, regular research papers and short communications. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced.